Receipt of and Spending on Cessation Medication Among US Adults With Employer-Sponsored Health Insur
Monday, March 22, 2021
Posted by: Natalia Gromov
Shrestha
SS, Xu X, Wang X, et al.
Receipt of and Spending on
Cessation Medication Among US Adults With Employer-Sponsored Health Insurance,
2010 and 2017.
Public Health Reports. February 2021. doi:10.1177/0033354920984155
Objective.
Studies examining the use of smoking cessation treatment and related spending
among enrollees with employer-sponsored health insurance are dated and limited
in scope. We assessed changes in annual receipt of and spending on cessation
medications approved by the US Food and Drug Administration (FDA) among tobacco
users with employer-sponsored health insurance from 2010 to 2017.
Methods.
We analyzed data on 439 865 adult tobacco users in 2010 and 344 567 adult
tobacco users in 2017 from the IBM MarketScan Commercial Database. We used a
negative binomial regression to estimate changes in receipt of cessation medication
(number of fills and refills and days of supply). We used a generalized linear
model to estimate spending (total, employers’, and out of pocket). In both
models, covariates included year, age, sex, residence, and type of health
insurance plan.
Results.
From 2010 to 2017, the percentage of adult tobacco users with
employer-sponsored health insurance who received any cessation medication
increased by 2.4%, from 15.7% to 16.1% (P < .001). Annual average number of
fills and refills per user increased by 15.1%, from 2.5 to 2.9 (P < .001)
and days of supply increased by 26.4%, from 81.9 to 103.5 (P < .001). The
total annual average spending per user increased by 53.6%, from $286.40 to
$440.00 (P < .001). Annual average out-of-pocket spending per user decreased
by 70.9%, from $70.80 to $20.60 (P < .001).
Conclusions.
Use of smoking cessation medications is low among smokers covered by
employer-sponsored health insurance. Opportunities exist to further increase
the use of cessation medications by promoting the use of evidence-based
cessation treatments and reducing barriers to coverage, including out-of-pocket
costs.
|
|